Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
Arnold, M., Laversanne, M., Brown, L. M., Devesa, S. S. & Bray, F. Predicting the future burden of esophageal cancer by histological subtype: International trends in incidence up to 2030. Am. J. Gastroenterol. 112(8), 1247–1255 (2017).
van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366(22), 2074–2084 (2012).
Al-Batran, S. E. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 17(12), 1697–1708 (2016).
Kato, K. et al. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 15(10), 1057–1066 (2019).
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398(10294), 27–40 (2021).
Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 10(1), 9–22 (2010).
Hamidi, H. & Ivaska, J. Every step of the way: Integrins in cancer progression and metastasis. Nat. Rev. Cancer 18(9), 533–548 (2018).
Guo, W. & Giancotti, F. G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell. Biol. 5(10), 816–826 (2004).
Loeser, H. et al. Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival. Sci. Rep. 10(1), 18411 (2020).
Fujita, S., Watanabe, M., Kubota, T., Teramoto, T. & Kitajima, M. Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett. 91(1), 145–149 (1995).
Trerotola, M. et al. Trop-2 promotes prostate cancer metastasis by modulating beta(1) integrin functions. Cancer Res. 73(10), 3155–3167 (2013).
Schiffmann, L. M. et al. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma. BMC Cancer 19(1), 531 (2019).
Plum, P. S. et al. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. BMC Cancer 19(1), 38 (2019).
Schroder, W. et al. Ivor-Lewis esophagectomy with and without laparoscopic conditioning of the gastric conduit. World J. Surg. 34(4), 738–743 (2010).
Holscher, A. H., Schneider, P. M., Gutschow, C. & Schroder, W. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann. Surg. 245(2), 241–246 (2007).
Messager, M. et al. Laparoscopic gastric mobilization reduces postoperative mortality after esophageal cancer surgery: A French nationwide study. Ann. Surg. 262(5), 817–822 (2015).
Mariette, C. et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N. Engl. J. Med. 380(2), 152–162 (2019).
Simon, R., Mirlacher, M. & Sauter, G. Tissue microarrays. Methods Mol. Med. 114, 257–268 (2005).
Essakly, A. et al. PIK3CA and KRAS amplification in esophageal adenocarcinoma and their impact on the inflammatory tumor microenvironment and prognosis. Transl. Oncol. 13(2), 157–164 (2020).
Schiffmann, L. M. et al. Dickkopf-2 (DKK2) as context dependent factor in patients with esophageal adenocarcinoma. Cancers (Basel) 12(2), 451 (2020).
Schallenberg, S. et al. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma. BMC Cancer 20(1), 12 (2020).
Loeser, H. et al. The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma. Oncoimmunology 8(5), e1581546 (2019).
Jahangiri, A., Aghi, M. K. & Carbonell, W. S. beta1 integrin: Critical path to antiangiogenic therapy resistance and beyond. Cancer Res. 74(1), 3–7 (2014).
Al-Jamal, R. & Harrison, D. J. Beta1 integrin in tissue remodelling and repair: From phenomena to concepts. Pharmacol. Ther. 120(2), 81–101 (2008).
Kato, H. et al. The primacy of beta1 integrin activation in the metastatic cascade. PLoS ONE 7(10), e46576 (2012).
Schober, M. & Fuchs, E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/focal adhesion kinase (FAK) signaling. Proc. Natl. Acad. Sci. U. S. A. 108(26), 10544–10549 (2011).
Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527(7578), 329–335 (2015).
Trerotola, M. et al. Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget 6(16), 14318–14328 (2015).
Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384(16), 1529–1541 (2021).
Bardia, A. et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann. Oncol. 32, 746–756. https://doi.org/10.1016/j.annonc.2021.03.005 (2021).
Nam, J. M., Chung, Y., Hsu, H. C. & Park, C. C. Beta1 integrin targeting to enhance radiation therapy. Int. J. Radiat. Biol. 85(11), 923–928 (2009).
Xie, Y.-H. et al. Role of integrin beta1 in the progression and chemoresistance of of esophageal squamous cell carcinoma. J. Cancer 13, 2074–2085. https://doi.org/10.7150/jca.68647 (2022).
Salem, M. E. et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Oncologist 23, 1319–1327. https://doi.org/10.1634/theoncologist.2018-0143 (2018).